Ignite Creation Date:
2024-05-06 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 1:53 PM
Study NCT ID:
NCT04702282
Status:
COMPLETED
Last Update Posted:
2021-01-08
First Post:
2021-01-06
Brief Title:
Population Pharmacokinetics of Ropivacaine
Sponsor:
Hvidovre University Hospital
Organization:
Hvidovre University Hospital
Study Overview
Official Title:
Population Pharmacokinetics of Ropivacaine Used for Local Infiltration Anesthesia During Primary Total Unilateral and Simultaneous Bilateral Knee Arthroplasty
Status:
COMPLETED
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study was to investigate the pharmacokinetics of free and total ropivacaine after unilateral and bilateral TKA A population model was successfully built and peak free ropivacaine concentration stayed below previously proposed toxic thresholds in patients undergoing unilateral as well as bilateral TKA receiving LIA with high dose ropivacaine
Detailed Description:
Thirteen unilateral TKA and fifteen bilateral TKA patients were included in the study All patients were operated in a well-described fast-track setup without use of drains or tourniquet21 A standard midline skin incision with a medial para-patellar capsulotomy was used All patients were operated with cemented CR components In bilateral TKA cases both knees were operated in one setting with the left knee always being operated first and the second knee being operated sequentially in the same setting immediately following closure of the first knee Patients undergoing unilateral TKA received spinal anesthesia with 2 mL 05 hyperbaric bupivacaine whereas patients scheduled for bilateral TKA received spinal anaesthesia with 3 mL 05 hyperbaric bupivacaine Local infiltration anesthesia was performed as previously described with 200 mL 02 ropivacaine 400 mg mixed with 1 mL 1 mgmL epinephrine injected periarticularly in each knee The first 50 mL were injected into the posterior capsule 100 mL were injected into medial anterior and lateral structures of the knee and capsule and the final 50 mL were injected in the subcutaneous tissue All patients were mobilized on the day of surgery and thromboembolic prophylaxis started 6-8 hours postoperatively with rivaroxaban tablets 10 mg given once daily until discharge No extended thromboembolic prophylaxis was given to any patient All patient received 1 g intravenous tranexamic acid preoperatively and 1 g 3 hours postoperatively
Preoperative blood samples were taken within a week of surgery including electrolytes hemoglobin and serum creatinine levels Baseline blood sample was taken just before incision of the first knee and additional blood samples were drawn at 1 5 30 and 60 minutes as well as 2 4 8 and 24 hours after incision following unilateral TKA and at 1 5 30 minutes after the incision of the first knee and 0 5 and 15 minutes after incision of the second knee as well as after 12 4 8 and 24 hours total 9 and 12 timepoints within 24 hours for unilateral and bilateral TKA respectively Patient demographics were recorded and included age gender height and weight
Ropivacaine measurement Ropivacaine concentrations were determined in plasma samples using liquid-chromatography coupled to mass spectrometry following a fully validated method
Preoperative blood samples were taken within a week of surgery including electrolytes hemoglobin and serum creatinine levels Baseline blood sample was taken just before incision of the first knee and additional blood samples were drawn at 1 5 30 and 60 minutes as well as 2 4 8 and 24 hours after incision following unilateral TKA and at 1 5 30 minutes after the incision of the first knee and 0 5 and 15 minutes after incision of the second knee as well as after 12 4 8 and 24 hours total 9 and 12 timepoints within 24 hours for unilateral and bilateral TKA respectively Patient demographics were recorded and included age gender height and weight
Ropivacaine measurement Ropivacaine concentrations were determined in plasma samples using liquid-chromatography coupled to mass spectrometry following a fully validated method
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None